Bringing Paradigm Changing Devices To Market – Shon Chakrabarti : 19

The Emerging Biotech Leader
The Emerging Biotech Leader
Bringing Paradigm Changing Devices To Market - Shon Chakrabarti : 19

“My primary advice is to get comfortable with discomfort right away and open your mind to how your particular skill set can benefit patients on this tremendously big scale.’” Shon Chakrabarti MD MPH, Vice President, and General Manager Chronic Venous Therapies, Inari Medical.

Episode 19 of the Emerging Biotech Leader commemorates a milestone. This interview features one of our first guests with a background in medical devices.

Unlike previous episodes, our guest also works outside of rare disease and targets a wider population of patients with unmet needs. And now for the big reveal on who this guest is: Shon Chakrabarti MD MPH, Vice President, and General Manager Chronic Venous Therapies, Inari Medical. Shon is an Interventional Cardiologist by training, bringing his education, experience, and expertise to Inari–they design tools to treat both Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT), focusing on the critical vessels of venous disease.

Kim hosts this episode solo which gives her and Shon ample time to cover a lot of ground, particularly:

  • His career transition from bedside physician to physician leader working across medical affairs, product development, GTM, and more at Inari
  • How past experience in treating patients helps Shon understand and approach changing the care pathway
  • The impact of evidence-based medicine on physician adoption and
  • The most surprising areas he has learned on the job

Whether you work in medical devices yourself or are considering a change from clinical practice to industry, this episode will help you understand how to think about a career pivot, what it takes to bring a medical device to market, and why it’s so critical to “listen to the evidence and the effects that your medical device has in the real world.”

We cover a few highlights here, but of course, the full interview contains so much more. Listen along and let us know, do you read these recaps before or after each episode? We’re open to gathering some data of our own.

Nothing Changes if Nothing Changes: From Practice to Product 

Treating patients one-on-one and providing bedside care seems like the complete opposite of working in the medical device space, but Shon threads his two roles, that of Physician and Physician Leader now in industry, together under the theme of change.

In fact, Inari isn’t the first medical device company Shon has worked for. While the devices may be different, and the disease states may be different, the idea in this sector of biotech is to help patients fully address their issues through advancements and innovations that demonstrate improved efficacy.

On this topic, Kim wanted to know Shon’s POV from the clinician side, specifically going against the “status quo” of current treatment modalities and what shift is required to, as she put it, “think about trying a new technology in a patient, whether it's a person in a study or speaking to other physicians about why they should adopt something that that is new?”

Shon cites three things that will help change occur.

  • Focus on the big, unmet needs
  • Provide tangible, visible evidence of the effect that the device is having on the patient
  • Show concrete data

Shon also shares that physicians do start to see the unmet need early on in various ways. “In your day-to-day practice, and in the cath lab and in the O.R., it's intuitive. You know when you're using something that hasn't been updated in 30 years where patient outcomes have been the same, and it isn't keeping up with other disease states.”

Listen in for more details and context as to how Shon has observed his three bullet points transforming physician adoption and patient outcomes in the cardiovascular field.

On Medical Affairs for Med Device 

The role and significance of Medical Affairs continues to be an important theme for biotechs, and it’s especially important for medical devices. As Kim touched on with Shon, “You're in the position where you're not just speaking about the modality and the science and educating on why this therapy is better than this one, but you're also hands-on training on the device itself.”

Listen to episode 13: “Making A Mark In Medical Affairs” 

Given Shon’s expertise in this and navigating the patient-physician-payer matrix, Kim was curious to hear more. “You're educating different segments in the medical community as well as the different sub-specialties that have trained in different ways over these decades, I would love your thoughts on all of this from a medical affairs perspective.”

Shon’s answer was perfect for the entire biotech industry: “One thing about medical affairs leaders–a good medical affairs leader is critical to the success of a device or pharma company. So there's a really important role there. It's not something that you dabble in or dip your toe in the water on. It's something you dive into.” 

Once again, this is where Shon’s prior experience treating patients comes into play.

“There's a certain perspective you get from taking direct care of patients. It's hard to describe, but it sort of involves this deep empathy and understanding of needs from a patient perspective. It also involves familiarity with health care delivery and the nuances of that and patient journeys, and to almost compare, it's like seeing a language you can functionally survive in an environment where you don't speak the language, but there's a lot lost in terms of context, and I think it's very much similar. So my experiences impact things like design considerations, they impact go to market strategies, they impact clinical research plans. There is really nothing that isn't touched by having been on that side of patient care.”

Learning On The Job: The Real-World Residency 

After a significant amount of time in med school and providing patient care, Kim was curious, where else did Shon learn GTM, product development, and even marketing for med devices?

He shared that he’s learned on the job. Here’s why that's been an advantage. Compared to peers who went a more traditional path for biotech, i.e. business school, Shon hasn’t just worked on one case study or one aspect of biotech. The same learner's mindset and drive that got him through rigorous med school training at Harvard is still alive and well.

“I feel like I'm almost in another training program, another residency here in these early years. I learn every day! And the interactions of interfacing with upstream marketing or reporting on strategy or interfacing with the business development team and M&A team about other technologies that are out there–I love it. I think it's a ton of fun probably because it's all new learning for me. So I think I chose to join companies that were not necessarily in the startup phase but a little more mature in terms of the teams they've developed. And that was probably good luck. But it resulted in an environment where I could safely insert myself into projects and learn from really great leaders around me: commercial leaders, marketing leaders, business and strategy leaders.”

The main takeaway here is to follow that calli...

More Episodes Like This


Daring to Fail Forward: The Mindset Catalyzing Healthcare Breakthroughs – Christian Howell : 34

This episode features an interview with Christian Howell, Chief Commercial Officer at Cognito Therapeutics, a biotech company pioneering a neurotechnology approach to treat Alzheimer's disease. Christian draws on his diverse background spanning the mili...

Avoiding Common Pitfalls in the Biotech Development Process – Dr. Thomas Lönngren : 33

Episode Overview: In this podcast interview, Ramin Farhood hosts Dr. Thomas Lönngren, an expert in drug regulation, approval, and market access. Thomas has an impressive career spanning over three decades, including a transformative tenure as the exe...

Redefining Roles: From Medical Practice to Biotech Ventures : 32

Biotech leadership thrives on diverse experiences and willingness to face new challenges. Effective leaders cultivate collaborative teams, promote adaptability, and balance innovation with financial constraints as they grow their companies.

Balancing Current Needs and Long-Term Goals in Biotech : 31

Building evolving biotech organizations requires balancing short-term demands with long-term objectives. Leveraging leaders as cross-functional connectors and prioritizing self-awareness and humility are paramount for driving organizational success.

Growing Early Biotech Startups Through Connection – Dan Bloomfield : 30

Gaining cross-functional exposure and leveraging expertise across the organization is invaluable. Building optimal teams through full-time hires and consultants, and cultivating an entrepreneurial mindset drives success in leadership roles.

Lessons In Biotechs with Bold Missions : 29

Large-scale studies and longitudinal data play key roles in demonstrating impact on outcomes, costs, and clinical utility. These research efforts, when meeting established standards, can support significant advancements in patient care approaches.


You don't have to go it alone! Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs.

This field is for validation purposes and should be left unchanged.